Latest Conference Articles

Mirvetuximab soravtansine plus carboplatin showed antitumor activity and a manageable safety profile in patients with recurrent platinum-sensitive ovarian cancer.

Bradley Monk, MD, discusses the final analysis of the phase 3 KEYNOTE-B96 trial in platinum-resistant recurrent ovarian cancer.

Alexander Olawaiye, MD, discusses the final overall survival data from the phase 3 ROSELLA trial in platinum-resistant ovarian cancer.

Significantly improved response rates were shown for liso-cel vs real-world data for SOC in later-line relapsed or refractory mantle cell lymphoma.

ECOG PS should be evaluated before initiating this agent, as patients with poorer PS may experience shorter life expectancy than reported in trials.

Sofetabart mipitecan elicited strong antitumor activity in recurrent platinum-resistant high-grade serous ovarian cancer.

The novel ADC DB-1311/BNT324 was effective in cervical cancer and PROC, regardless of prior treatment or histology

The B7-H3–targeting ADC demonstrated encouraging responses across multiple gynecologic cancers in a phase 1/2 trial.

Sun Yang, MD, discusses the activity of frontline cadonilimab plus chemotherapy in patients with recurrent/advanced endometrial carcinoma.

Bhavana Pothuri, MD, discusses phase 2 data with trastuzumab pamirtecan (DB-1303/BNT323) in pretreated patients with HER2-expressing endometrial cancer.

Single-agent rezatapopt showed efficacy and safety irrespective of patients' platinum status, prior bevacizumab or PARP inhibitor exposure, or FRα expression.

The B7-H4–targeted ADC produced ORRs of 62% and 67% in patients with PROC and endometrial cancer, respectively, in the phase 1 BEHOLD-1 study.

Cadonilimab combined with chemotherapy demonstrated robust efficacy and a favorable safety profile in advanced or recurrent endometrial cancer.

Megan Hutchcraft, MD, discusses the use of social media to amplify her online presence in gynecologic oncology research and education.

Roisin E. O'Cearbhaill, MD, discusses a phase 1/2 trial assessing REGN5668 combined with other targeted agents in recurrent endometrial or ovarian cancer.

Patients who received first-line niraparib as maintenance therapy had high resolution rates and low number of discontinuations due to hematologic PSEOIs.

A significant increase in treatment completion was observed among Black women with high-risk endometrial cancer who received 1:1 peer support.

Trastuzumab pamirtecan achieved ~50% ORR in pretreated HER2-expressing endometrial cancer, earning FDA breakthrough designation per phase 1/2 trial data.

With 1 year of additional follow-up, avutometinib plus defactinib showed durable efficacy with no new safety concerns in LGSOC.

Results from NRG-GY019 establish chemotherapy followed by letrozole as the definitive SOC for newly diagnosed stage II-IV low-grade serous ovarian carcinoma

Abemaciclib plus letrozole was safe and active in advanced/recurrent endometrioid endometrial carcinoma.

Relacorilant plus nab-paclitaxel cuts death risk by 35% and extends survival to 16 months in platinum-resistant ovarian cancer, per final ROSELLA trial data.

Zosia Piotrowska, MD, MHS, discusses potential new TKIs, continued challenges, and ongoing frontline trials in EGFR exon 20 insertion–positive NSCLC

Read below to hear from Drs Markman and Slomovitz on the sessions and abstracts they’re looking forward to at this year’s SGO Annual Meeting on Women’s Cancer.

Use of ruxolitinib before, during, and after allogeneic stem cell transplant was associated with low rates of GVHD in myelofibrosis.

Cemiplimab plus chemotherapy produced variable outcomes by genomic profile in patients with nonsquamous NSCLC.

Erda-iDRS was safe and produced early efficacy signals in FGFR-altered NMIBC.

Enolen was safe and feasible for the treatment of patients with early-stage prostate cancer.

Jae Park, MD, discusses the importance and utility of MRD testing in the current acute lymphoblastic leukemia management field.

Gotistobart improved response rates and overall survival vs docetaxel in pretreated squamous NSCLC in stage 1 of the PRESERVE-003 trial.